Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Sanne LofMaarten KorrelJony van HilstAdnan AlseidiGianpaolo BalzanoUgo BoggiGiovanni ButturiniRiccardo CasadeiSafi DokmakBjørn EdwinMassimo FalconiTobias KeckGiuseppe MalleoMatteo de PastenaAles TomazicHanneke WilminkAlessandro ZerbiMarc G H BesselinkMohammed Abu Hilalnull nullPublished in: Annals of surgical oncology (2019)
In this international multicenter cohort study, NAT for resected PDAC in pancreatic body or tail was associated with less morbidity and pancreatic fistula but similar overall survival in comparison with upfront resection. Prospective studies should confirm a survival benefit of NAT in patients with PDAC and splenic vessel involvement.